Mark Lazarus, MD, PhD

AstraZeneca
Cambridge, United Kingdom

Experimental Medicine Physician Immunology

Disclosure information not submitted.

Presentation(s):

• 0360: Longitudinal Variation of Proteomic Biomarkers That Correlate with Efficacy Endpoints: Results from a Phase 3 Trial of Anifrolumab in Moderate to Severe Systemic Lupus Erythematosus

  Saturday, November 12, 2022
  1:00 PM – 3:00 PM Eastern Time